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Abstract
Neurodegenerative diseases affect around one billion people globally that are characterized
by irreversible degeneration of brain tissues. These diseases cause serious effects on patients
degrading their brain functions and causing enormous physical and mental health issues.
Parkinson's disease (PD) is one of the most common neurodegenerative disorder affecting millions
of people worldwide which results from loss of dopaminergic (DA) neurons in the mid-brain.
Unfortunately, no medical treatment is effective to date for these significant brain disorders, except
some symptomatic therapies only focusing on improving the quality of patient’s life.
Two current approaches hold great promise in targeting PD as well as other
neurodegenerative diseases, by surgically implanting electrodes for deep brain stimulation (DBS)
and transplanting healthy neuronal cells at the site of tissue loss, due to disease in the brain.
However, cells for transplantation need to be delivered via a scaffold. Nerve regeneration in a
scaffold of appropriate biomaterial is of great importance while being implanted inside the animal
body for further clinical applications. In this dissertation, both approaches for treating PD were
incorporated by in vitro studies using surface-engineering and tissue-engineering techniques. For
the first approach, graphene oxide (GO) coatings on commercially available 316L stainless steel
(SS) surfaces was done to reduce the neurotoxicity of SS and modified surfaces showed
hydrophilicity, biocompatibility, cell proliferation, and decreased reactive oxygen species (ROS)
expression with SHSY-5Y neuroblastoma cell lines.
Transplantation of stem cells in vivo is another approach for reducing the progression of
PD by reversing the loss of affected DA neurons. So, our second approach included differentiation
of mesenchymal stem cells into DA neurons using Sonic hedgehog, Fibroblast growth factor, Basic
fibroblast growth factor and Brain-derived neurotrophic factor, while they were cultured within
collagen coated three-dimensional (3D) Graphene foams. 3D multilayer graphene scaffold could
mimic the actual brain tissue environment and more closely exhibit morphologies, functions and
other necessary characteristics compared to 2D culture on tissue culture plastic. The graphenevi

based scaffolds were not cytotoxic as cells seemed to retain viability and proliferated substantially
during in vitro culture. These results suggest the utility of Graphene-based materials towards
neuronal and stem cell culture, which is an important step for neural tissue engineering
applications.
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Chapter 1: Introduction
Among all organs in our body, brain is the most complex containing billions of nerve cells
and fibers that are in turn connected by trillions of connections called synapses [1]. The brain is
anatomically divided into specialized areas which work together to receive inputs from the sensory
organs and send outputs to the muscle tissues. It controls all the voluntary and involuntary
functions of the body. Any condition that affects this complex anatomy can result in chronic
conditions such as those observed in neurodegenerative disorders including Parkinson’s disease
(PD), Alzheimer’s (AZ) and Amyotrophic Lateral Sclerosis (ALS), which can affect our
movement and thinking abilities.
Nervous system consists of two main parts, central nervous system (CNS) and peripheral
nervous system (PNS). The CNS consists of brain and spinal cord which controls most functions
of the body and mind, while the PNS includes all the other parts of the nervous system except brain
and spinal cord. The CNS serves the purpose of communication, homeostasis and mental activity.
Nerve tissue, the primary tissue of the central nervous system consisting of many cells including
neurons and glial cell regulates the bodily activities. Neurons are electrically excitable cells and
primary component of the central nervous system that transmit and receive messages through
electrical and chemical signals via synapses in a neural network. Degeneration or death of neuronal
cells leads to neurodegenerative disorders which constitutes the greater portion of neurological
diseases. These types of diseases include AZ, PD, ALS, and Huntington’s disease, most of the
time caused by genetic mutations, environmental health problems, aging, brain injury and some
intracellular mechanisms [2]. Current treatment for neurological disorders includes variety of
medications and treatments, physical therapies and sometimes even surgical interventions, all of
which cannot stop the breakdown of neuronal cells and as a result cannot restore the normal brain
functions of the patient [3]. The most common medicines- carbidopa, levodopa and dopamine
agonists can control some symptoms of PD, but have lots of side effects including dizziness,
restlessness, headache, nausea, stomach pain, and low blood pressure. Furthermore, medicines for
1

PD can only control the motor symptoms [4]. Deep brain stimulation (DBS) surgery with
implantable electrodes is another treatment used to treat more advanced cases and offer
symptomatic treatment of PD, especially in those where the drugs are not effective to improve the
condition of the patients. DBS surgery reduces the symptoms like bradykinesia and rigidity but
not tremor [5]. So even after the surgery, the patients need to depend on the medications for some
of the motor symptoms.
Neurological disorders have significant impacts on the world’s economy and represent a
large portion of global burden of disease [6, 7]. According to ITIF (Information technology and
Innovation foundation), brain disorders cost the U.S. economy more than $1.5 trillion per year.
Hence, now researchers are investigating how tissue engineering and regenerative medicine could
be used to find innovative ways to treat or prevent the brain diseases in a more economically
feasible way.
1.1 Background
Parkinson’s disease (PD) is increasingly being identified as a highly complex
neurodegenerative disorder with complications arising from co-occurring pathologies and diverse
contributing risk factors, such as ageing, genetics and environmental toxins. The disease is
considered as the second most common neurodegenerative disorder encapsulated by the loss of
midbrain dopaminergic (DA) neurons in the substantia nigra pars compacta (SNPC) (Figure 1.1)
affecting mostly the aged people as well as young adults. [8, 9]. About 10%-20% of those
diagnosed with Parkinson’s disease are under age 50, and about half of those are diagnosed before
age 40 [10]. Approximately 60,000 new cases of Parkinson’s are diagnosed each year in the United
States, meaning somewhere around 6,000 – 12,000 are young onset patients [11]. Thus, PD has
been extremely important to diagnose and treat at an early onset compared to later and more
advanced stages of the disease in affected individuals.
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Figure 1.1: Parkinson’s patients have less dopamine, shown in (a) healthy patients have
more dopamine producing neurons and (b) Parkinson’s patient’s dopamine producing cells are
damaged or dead [adopted from NIH website]

Micronutrient deficiency has remarkable effects on neural tissue functions. There are
certain micronutrients, usually some vitamins and minerals, that can prevent the onset of
Parkinson’s disease as well as other neurodegenerative disorders in youth, such as magnesium,
folic acid, zinc and so on [12, 13]. Many of the non-motor symptoms like dementia and dysphagia
can be prevented by intaking vitamins or phytonutrients. In PD, non-motor symptoms might be
responsible for the impairment of fluid and micronutrient balance, and pharmaconutrient
interactions [14]. Zinc performs important functions in the early development and maintenance of
the brain in a fetus. A fetus in a pregnant women being low in Zn and high in Cu may later manifest
themselves as schizophrenia, autism or epilepsy as well as corresponding increase in oxidative
damage, eventually leading to PD [15]. Therefore, efforts must be directed to prevent the onset
and progression of PD by controlling the diet, nutrition, and nutrients along with environmental
3

risk factors by the side of current treatment which is mainly focused on symptomatic management
[16].
The loss of DA neurons occurs with formation of Lewy bodies and lewy neurites, which
are mainly formed by insoluble aggregates of α -synuclein (coded by SCNA). A large number of
motor and non-motor features including muscle rigidity, resting tremors, bradykinesia, depression,
cognitive dysfunction, and sleep disorders appear when 60–80 % of dopamine (DA) neurons are
degenerated causing the neurochemical changes in the striatum due to loss of nigrostriatal axon
terminals [17, 18]. In most of the cases, PD is sporadic having different pathologies, instead of
being familial PD (fPD), which suggest that the genetic factors play a minor role in causing typical
PD [19]. Patients with autosomal-dominant fPD typically show extensive formation of Lewy
bodies in different parts of the brain unlike patients with autosomal-recessive fPD [20]. Mutations
of the proteins SNCA, LRRK2, PARK2, PINK1, and PARK7 possess important roles in the
pathogenesis of the disease among which SNCA and LRRK2 are leading to the autosomaldominant forms of the disease [21]. Lewy bodies composed of α-synuclein encoded by SNCA
gene aggregate in both inherited and sporadic forms of the disease [22]. Ten different subtypes of
DA neurons have been identified in the whole brain among which A8, A9, and A10 reside in the
midbrain [23]. The loss of the pigmented A9 DA neurons of the ventrolateral pars compacta which
control movement gives rise to the symptoms of PD [24]. Non-motor symptoms like olfactory
dysfunction, sleep disturbance, dementia and smell loss are caused by the aggregation of α synuclein forming Lewy bodies in various parts of the brain of a PD patient. The spread of α synuclein corresponding to the worsening of Symptoms in Parkinson’s is shown in Figure 1.2 [25].
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Figure 1.2: Spread of α -synuclein corresponding to the worsening of Symptoms in Parkinson’s
is shown in (a) autonomic and olfactory disturbances, (b) sleep and motor disturbances and (c)
emotional and cognitive disturbances.

Though existing treatments for PD including dopamine replacement drugs such as
levodopa, carbidopa and deep brain stimulation (DBS) are effective in improving the symptoms
of the patients, they are not able to stop PD progression [26, 27].
DBS is an established open-brain-surgery treatment for PD which involves implantation of
neural electrodes which sends electrical impulses to the specific targets in the brain for deep brain
recording. Besides, neural implants have significant role in understanding the disease pathology.
In vivo recording of neural activity by brain electrodes contains the risk of scar tissue formation
in case of functional brain signal recording. The scar tissue encapsulates the electrode, creating a
physical barrier between the electrode surface and the brain. Thus, the electrode–brain interface of
these devices needs to withstand the challenge of chronic recording with minimal effect on the
surrounding tissue [28]. Hence, modifying the surface of the electrode by biomolecule
immobilization applying surface engineering techniques enhances the overall biocompatibility and
5

efficacy of the electrodes [29]. Several coating materials have been used to reduce the level of
scarring and enhancing the biocompatibility of the electrodes for deeper brain sites, including
diamond-like carbon [30], SiC [31], TiN [32], TiO2 [33], polymers [34] and biological moieties
such as heparin [35] and dopamine [36] are usually adopted for a variety of applications. Each of
these coating materials have inherent limitations of instability. Specifically for neural implant
electrodes iridium oxide coatings [37], multiwalled carbon nanotubes (MWNTs) and gold coatings
[38] [39] and a conductive polymer coating has been shown to improve the electrochemical
properties of electrodes [40]. However, all implantable electrodes in Chronic Neural Interfaces
(CNI) encounters a common problem of deteriorating in performance of recording capabilities
over time because of tissue injury and adverse reactions with the coating materials of the implants
[41]. To solve this issue, novel inert materials need to be explored as coating materials for neural
electrodes.
A molecular-level road-mapping of PD progress is challenged by the lack of access to
affected human DA neurons along the disease trajectory. Besides, animal studies designed to
provide an advanced prototype of PD often suffer from differing vulnerabilities to disease-causing
factors. Therefore, stressors or genetic risk factors, which play an important role in the
pathogenesis of PD in humans, may not be revealed by animal studies. As studying neuronal cell
death in human brains is extremely difficult and invasive, development of in-vitro models of DA
neurons would make it possible to understand cellular and molecular mechanisms of the
neurodegenerative disorders and novel therapeutic strategies [42]. Different cellular models have
been established to investigate the mechanisms underlying PD [43]. Current models for studying
PD rely on neuronal cell lines such as SHSY-5Y, N27, N2a and PC-12 as a means to define disease
causals and progress. However, these cell types neither satisfactorily reproduces cardinal features
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associated with the disease nor facilitate drug screening efforts against PD. As a result, discoveries
arising from such cellular models, which are usually not based on human DA neurons, may not
fully reflect true disease pathogenesis and pathology that would otherwise likely be observed in
DA neurons [44].
Recently several researchers are trying to replace lost DA neurons using stem cells such as
neural stem cells (NSCs), embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), and
induced pluripotent stem cells (iPSCs). Human induced pluripotent stem cell (iPSC) and human
Mesenchymal Cell (MSC) lines are particularly advantageous to study PD progression and may
fill the gap in aforementioned PD models. For example, iPSC lines generated from idiopathic
patients lacking known PD mutations offer the opportunity to investigate the degree to which
patient cells are inherently dysfunctional (due to the contribution from background genetic
susceptibility). A second potential advantage in iPSC-derived cultures is that they facilitate in vitro
clinical trials, whereby the genetic diversity seen in populations can be captured in vitro. This
permits the investigation of genotype-dependent drug efficacies. MSC have advanced in their
applications to form diverse tissue types and possess the potential to treat a wide range of acute
and degenerative diseases making them particularly attractive to PD studies and treatment.
1.2 Rationale and Hypotheses
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder characterized by
progressive slowness of movement and loss of the brain chemical dopamine, with no known cure.
Molecular level investigations have revealed the accumulation and aggregation of toxic
proteins/biomarkers such as -synuclein and synphilin-1 in DA neurons affected by PD. Current
treatment options for PD includes implantation of electrodes for DBS. However, all implantable
electrodes encounter a common problem of deterioration in performance of recording capabilities
over time because of tissue injury and adverse reactions. Therefore, studies must be done to
7

understand the modulation and disease progression of PD in cell culture models in vitro, to devise
therapeutic strategies to inhibit the progression of PD.
Stainless steel (SS) alloys are often used as biomedical implants with applications in
cardiovascular, orthopaedic and dentistry due to their superior mechanical properties. However the
neurotoxicity of iron present in stainless steel makes it unsuitable as neuronal implants [45]. The
use of inert materials is of special importance for neural electrodes used for DBS, useful in a
therapy of movement disorders including PD [46]. Acute misbalance of brain iron homeostasis has
been linked to acute neuronal injury following cerebral ischemia [47]. Free iron is known to
catalyse the conversion of superoxide and hydrogen peroxide into hydroxyl radicals, which
generate oxidative stress leading to subsequent apoptosis of neurons [47]. Besides, bare metallic
SS surfaces are often affected by biological corrosion in vivo [46], and etching releasing sub-lethal
concentrations of metallic ions which could exacerbate the pro-inflammatory and fibrotic reactions
[47, 48]. Surface modification plays an effective role to alleviate these adverse physiological
responses to the SS implants. Studies have shown that graphene oxide (GO) films allowed the
effective proliferation of human and mammalian cells with limited or no cytotoxicity [49, 50].
Specifically, GO has been recently shown to promote the growth of neuronal cells [49, 51], human
osteoblasts [52] and even promoted osteogenic differentiation of human mesenchymal stem cells
[53]. In one of our previous study, GO-coated surfaces significantly enhanced endothelial cell
adhesion, proliferation and reduced ROS expression compared with bare implant surfacese. Such
characteristics seem to indicate that GO may be an ideal candidate for coating implant surfaces
along with the fact that GO is also chemically inert, electrically-conductive and durable [54-56].
These reports motivated us to further explore the feasibility of coating bare 316L SS surfaces with
GO, and to determine the ability of these GO-coatings in enhancing the biocompatibility of
existing 316L SS implant surfaces. In addition GO-coatings adhere strongly to underlying surfaces
thereby forming an over–coating and a protective layer at the same time [57]. GO can be applied
as surface coatings of electrodes currently used in DBS used to treat PD patients. We hypothesized
that GO coated SS surfaces will have optimized properties for application as neural implants,
8

will promote neural outgrowth and reduce the progression of degenerative pathologies in
diseased PD neurons. Further we believe this technique of GO-coating could be applied to other
metallic implant surfaces wherever the development of such protective coatings is necessary.
Another therapeutic approach for PD is cell replacement therapy (CRT), a restorative
therapy designed to secure a long-lasting relief of patients’ symptoms. Cell based replacement
therapy utilizing stem cells holds immense potential as a long-term treatment for PD. MSC can
serve in stem-cell-replacement-therapy which is a powerful tool for investigating disease
pathology and for advancing clinical therapies. To make feasible, studies involving the role of
material interactions with human DA neurons in a dish, we differentiated human mesenchymal
stem cells (MSC) into DA neurons [58]. Using these human stem cell differentiated DA neuronPD transfected cell culture models, we aimed to study interactions between DA neurons and threedimensional (3D) graphene foam (GF) that will reduce or mitigate the progression of PD in-vitro.
On the basis of strong preliminary data [59], we hypothesized that culture atop nanotextured
Graphene-based substrates will be extremely effective in reducing the progression of PD
pathogenesis in human MSC differentiated DA neuron-PD transfected cells. The novelty of this
study is based on the hypothesis that differentiating mesenchymal stem cells in a threedimensional (3D) scaffold into DA neurons can be used for cell transplantation therapy for the
treatment of Parkinson’s disease.
1.3 Objectives
The objective of this research project was to develop biocompatible and adherent thin film
coated SS electrodes for use in DBS therapy as a potential alternative to high cost Platinum (Pt)
electrodes for treatment of PD in affected population. We aimed to develop a novel coating
utilizing GO to surface-modify existing SS surfaces to enhance their biocompatibility and
functional uniqueness. We are interested in using less-toxic polymer-free materials which will
confer biocompatibility and conductivity for SS implant surfaces. The first aim of this study was
to develop a GO-coating for surface modification of existing SS implant surfaces, to assess and
9

characterize the material properties, resistance to degradation and unique functionalities including
conferring of GO-coatings and to assess the biocompatibility of the GO-coated SS implants by invitro cell culture experiments.
In contrast, stem cells can be differentiated to grow dopamine-producing DA neurons in
vitro, enabling studies exploring the genetic basis for such diseases on a dish in vitro. Further, CRT
using stem cells is considered as a potential approach to treat PD, given that the progressive
neuronal loss of DA neurons characterizes them. Human iPSCs reprogrammed from adult human
somatic cells; and human MSCs from the bone-marrow or adipose represent a promising unlimited
cell source for generating patient-specific cells for biomedical research and personalized medicine.
The second aim of the study was to differentiate DA neurons from MSC. This MSC differentiated
DA neuron-PD induced cell culture model will become a powerful tool and enable modeling and
treatment of PD in a dish in vitro. In addition to revealing the mechanisms involved in modulating
the disease progression in PD, our future studies will test the ability of potential novel material
interventions to restore or reduce the level of PD in affected DA neurons. Accordingly, the study
was executed.
Specific Aim 1: To develop a GO-coating for surface modification of existing SS implant
surfaces characterizing the material properties and testing biocompatibility of the GO-coated SS
implants by in-vitro cell culture experiments.
Specific Aim 2: To test the efficacy of 3D multilayer Graphene-based scaffolds towards
the adhesion, proliferation and maintenance of neuronal-phenotype by MSC differentiated DA
neurons scaffolds in reducing the progression of PD pathogenesis in MSC differentiated DA
neurons.
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Figure 1.3: The objective of this study is to reduce Parkinson’s disease progression by surface
modification and differentiating dopaminergic neurons from mesenchymal stem cells.

In Figure 1.3, the two potential therapeutic approaches for PD is shown as symptomatic
treatments and fundamentally understanding the disease progression using stem cell derived DA
neurons. The objective of this study aimed in both approaches by coating electrodes for DBS by
novel biomaterial and differentiating DA neurons in a scaffold for implantation. In the first study,
our objective was to utilize a commercially available 3D biocompatible scaffold made of GF for
culturing MSC and differentiating into DA neurons. Our hypothesis was that differentiated DA
neurons when cultured in a 3D hydrogel-based scaffold at a high density, will more closely exhibit
morphologies, functions and other necessary characteristics compared to 2D culture on tissue
culture plastic. However, as the GF is extremely hydrophobic, to make it hydrophilic collagen gel
was used as a coating material which is hydrophilic but lacks mechanical stability and electrical
conductivity, whereas GF is hydrophobic but electrically conductive [60]. So, to combine and
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extract the best of both materials, collagen was deposited over the GF and crosslinked using
genipin [61], which a hydrophilic, porous yet conductive scaffold ideal for neuron culture.
This work will significantly contribute by allowing us to study interactions between healthy
DA neurons, their synapses and communications, and predict mechanisms involved in DA neuron
apoptosis during injury and disease. As studying neuronal cell death in human brains is extremely
difficult and invasive, development of in vitro models of DA neurons would make it possible to
understand cellular and molecular mechanisms of the neurodegenerative disorders and novel
therapeutic strategies. This study is innovative as the 3D tissues will facilitate investigation of
human DA neuronal function and disease and may be adaptable for engineering other 3D tissues
from different stem cell types. The interactions between DA neurons (including healthy and PD
induced state) and Graphene-based substrates can lead to material-based approaches for treatment
of not only PD but will undoubtedly also be useful to other research groups and impact other
synucleinopathies such as Huntington’s, ALS and Alzheimer’s.
In the second study, MSC was differentiated into DA neurons using established protocols
[58], and characterized using antibodies for -III tubulin, tyrosine hydroxylase and their dopamine
secretion. For this differentiation process, MSC was seeded atop 3D GF scaffold and then induced
for differentiation. The extent of cell adhesion, proliferation and maintenance of DA neuron
morphology of cells grown on Graphene-based substrates was observed, quantified and compared
to DA neurons passaged on control cell culture substrates. DA neurons grown atop 3D GF scaffold
exhibited pronounced neuronal phenotype with longer neurite extensions. The result of this study
demonstrated GF as a novel scaffold for adhesion, proliferation, differentiation and maintenance
of their neuronal phenotype by MSC derived DA neurons.
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Chapter 2: Current approaches for symptomatic treatment of PD
Parkinson's disease (PD) is a progressive neurodegenerative disease affecting tens of
millions of people worldwide and associated with socioeconomic burden [62]. The main
characteristic of this disease is damage or loss of dopaminergic (DA) neuronal cells which cannot
be replaced or regenerated by the nerve tissue in the patient’s brain. For repairing the damaged
neural function, brain electrodes can be implanted at the site of injury by open-brain surgery.
Another emerging treatment is cell replacement therapy (CRT), tissue engineering patient’s own
stem cells which can be differentiated into neuronal cells in presence of growth factors to reduce
the progression of neurodegeneration. The scaffold for transplanting the stem cells should be
biocompatible, electrically conductive, and able to imitate the mechanical properties of a living
tissue and should ensure not to get rejected by the host or cause any inflammation.
At present, the dopamine producing drugs like levodopa and carbidopa are the standard
treatment for PD, though long-term use of levodopa is associated with the development of motor
complications. Thus, the functional neurosurgery deep brain stimulation (DBS) of the subthalamic
nucleus (STN) with implanted electrodes has been an effective treatment to date [62]. In this
standard surgical procedure, macroelectrodes are implanted in the STN facilitating the prior
functional localization of the target through intra-operative stimulation and microelectrode
recordings of the activity of single neurons. Adequate targeting is confirmed through postoperative imaging following the connection and insertion of the subcutaneous stimulator under
general anesthesia [62].
The symptomatic treatment with medication or DBS functional neurosurgery improve the
motor symptoms and quality of life of the patient’s life in the early stages of the disease, but after
a few years of dopaminergic therapy, patients become progressively more disabled [63]. They
suffer from the motor symptoms, such as speech impairment, abnormal posture, gait, balance
problems etc. and nonmotor signs, such as autonomic dysfunction, mood and cognitive
impairment, sleep problems, pain and other drug-related side effects sooner or later [63].
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2.1 Biomaterial coating for brain electrodes in DBS
Ongoing research is exploring the feasibility of fabricating devices which record the
electrical signals from the brain with the help of electrodes and analyzing and decoding the signals
will help the paralyzed patients and amputees to move by bionic limbs [64]. The electrodes can be
implanted in the patient’s brain by open brain surgery or non-invasively through the blood vessel
[65]. These types of devices can be used for peripheral nerve regeneration by electrically
stimulating the neuronal cells and as well as in case of central nervous system by establishing
connections between the transplanted 3D scaffolds. Neural implants increases our understanding
about the design and application of prosthetic devices and the functional stimulation and recording
from the central and peripheral nervous system [29]. These kinds of devices have shown great
promise in treating neurological disorders also, such as PD.

Figure 2.1: DBS electrodes are left inside the brain and the pulse generator is implanted
under the skin over the chest [66]

14

DBS uses special electrodes to stimulate the Globus pallidus or subthalamic nucleus for
the surgical treatment of PD. There are several steps to place the electrodes into the target areas of
the brain during surgery. The target areas are located using computed tomography (CT) or
magnetic resonance imaging (MRI) scanning [67]. Electrode recording technique is used to map
and target the specific areas needed to reach at the later stage of the surgery. After identifying the
correct location, the electrodes are implanted. The loose ends of the electrodes are connected to
the impulse generators [67]. The electrodes for deep brain stimulation is left in the brain and are
connected by a wire to a pacemaker-like device which generates the electrical stimulation being
implanted under the skin over the chest as shown in Figure 2.1 [66]. In a recent research it has
been proved that DBS does not relieve long-standing treatment-resistant depression any more
effectively, although administering it is both safe and feasible [66].
Biomaterials incorporate extracellular matrix (ECM) molecules that have adhesive and
growth promoting properties and have been used to deliver neurotrophic factors like brain derived
neurotrophic factors for differentiation of stem cells into neurons. These materials have intrinsic
properties that promote growth, such as the use of conductive materials to modulate the neuron’s
electrical and chemical activities. Biomaterials in nerve tissue engineering enhance the
regenerative process by creating a growth promoting environment and directing axonal growth to
reconnect nerves for functional recovery [68]. The effectiveness of the neural implants decreases
with time due to glial scar tissue formation and fibrous encapsulation that electrically and
mechanically isolates the device from the nerve tissue [69]. To avoid these problems, several
approaches like immobilization of biomolecules on the electrode surface have been explored.
Surface modification by electrostatic layer-by-layer (LbL) self-assembly technique was introduced
by Decher in 1991 [70]. The underlying principle for the LbL technique is the attractive
electrostatic force between a charged surface and an oppositely charged polyelectrolyte. The LbL
technique is a promising approach for the construction of thin films containing macromolecules,
such as proteins [71] with targeted properties onto a variety of substrates. In one study, alternating
polyelectrolytes, either polyethyleneimine (PEI) or chitosan (CH), and proteins, either laminin or
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gelatin, were used to fabricate multilayer films built up by LbL deposition on silicon wafers with
a very thin oxide layer. Silicon wafers were chosen as the substrates because silicon is the most
widely used material for neuronal electrodes. The constituents of these coatings were chosen for
their general ability to promote neuronal attachment and differentiation. For instance, laminin
plays a crucial role in the developing and maturing central nervous system, e.g. in cell migration,
differentiation and axonal growth [72]. It has been extensively used as a substrate for the studies
on the growth of neurons in vitro. These researchers used the response of chick cortical neurons to
test the biocompatibility of the coatings and utilized quartz crystal microbalance (QCM) to
characterize the coatings which confirmed nanoscale coatings via LbL assembly and enhanced
chick cortical neuron adhesion and differentiation. There was no adverse effect after 7 days in
physiological conditions and on impedance of the electrodes, confirmed by enzyme-linked
immunosorbent assay (ELISA) and impedance spectroscopy. The nanoscale coating proved the
potential to significantly impact the biocompatibility and performance of the electrodes [29].
In major neurological diseases such as PD, spinal cord injury and stroke, tissue engineering
and regenerative medicine aims to replace the damaged tissue using different stem cells,
particularly MSCs as they have shown strong potential in neuronal cell regeneration [73]. The use
of stem cells in these applications has also been combined with electric stimulation [74] and
biomaterial scaffolds to provide mechanical support and promote neural growth and neurogenesis
at the injured areas. Electrical stimulation in treating various neurological conditions, especially
Parkinson’s disease is currently another significant research [67]. The development of deep brain
stimulation has required designing biocompatible materials with conductive properties and the
ability to support the growth of neural tissue at the implantation site. In this application, surface
modification and stem cells can be used to further improve the functionality and long-term stability
of the electrodes by tailoring the material-tissue interface for implantable MSC-coated brain
electrode and guide the stem cells into the neuronal lineage in vivo.
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2.2 Stem cell therapy
Different adult stem cells such as, neural stem cell (NSC), induced pluripotent stem cell
(iPSC) and mesenchymal stem cell (MSC) have been extensively used in tissue engineering for
nerve regeneration by differentiating them into neuronal cells. Among all types of stem cells, MSC
seemed the most promising in respect of their capacities to differentiate toward dopaminergic
neurons and to release neurotrophic factors which is very important for neurodegeneration therapy.
Also, they are able to produce different molecules with immunomodulatory, neuroprotective,
angiogenic, chemotactic effects and that stimulate differentiation of resident stem cells [75, 76].
In cell transplantation therapy, MSC promotes endogenous neuronal growth, decreased
apoptosis, reduces levels of free radicals, encourages synaptic connections from damaged neurons
and regulates inflammation, primarily through paracrine actions [75, 77]. MSCs transplanted into
the brain have been demonstrated to promote functional recovery by producing trophic factors that
induce survival and regeneration of host neurons [75, 77]. Therapies mainly capitalize on the
innate trophic support from MSCs or on augmented growth factor support, such as delivering
brain-derived neurotrophic factor or glial-derived neurotrophic factor into the brain to support
injured neurons, using genetically engineered MSCs as the delivery vehicles [75, 77].
Biomaterials employed as three-dimensional (3D) scaffold provide stem cells with an
appropriate microenvironment to reproduce the functions of the damaged tissue. Cell-seeded
scaffolds are more effective at directing the growth by localizing the presence of growthstimulatory molecules [78]. Hydrogel scaffolds can be categorized as natural or synthetic, such as
collagen, fibrin, and hyaluronic acid are natural scaffolds being generally more biocompatible, and
polylacticoglycolic acid (PLGA) or polyethylene glycol (PEG) are synthetic scaffolds having ideal
mechanical and chemical properties. Main properties in designing the scaffolds for stem cell
transplantation are mechanical properties, cell adhesion and biocompatibility, polymerization and
degradation rate. Graphene foam (GF), a 3D porous structure, has been utilized as a promising
candidate for tissue engineering scaffold as it may incorporate topographical, chemical and
electrical cues to provide an environment for stem cell tissue engineering for nerve regeneration
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[79]. Graphene has been used as a scaffold because it is highly biocompatible and has low toxicity
having excellent electrical and mechanical properties. Table 2.1 shows how graphene and its
derivatives are used in stem cell tissue engineering applications [80].

Table 2.1: Stem cell-based tissue engineering on different graphene scaffolds

Scaffold
Reduced GO

Cell type

Result

Neural Stem Cell The neuronal differentiation of human NSCs

(rGO)/ TiO2

Ref.
[81]

on rGO/TiO2 substrate is greatly higher
compared to GO/TiO2 and TiO2 substrate.

GO

Embryonic Stem
Cell

GO substrate demonstrates an important

[82]

enhancement of dopamine neurons
differentiation

Graphene 3D foam Neural Stem Cell Graphene 3D foam has a greater

[83]

electrical stimulation performance
when compared to graphene 2D film.
Graphene

coated Neural Stem Cell Graphene substrate is an excellent cell-

glass

[84]

adhesion layer during the differentiation
process and induces the differentiation more

Graphene film

Neural Stem Cell NSCs seeded on graphene film differentiate and [85]
form functional neuronal networks

Fluorinated

Mesenchymal

graphene

Stem Cell

Fluorinated graphene enhances cell adhesion
and proliferation of human BMMSCs
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[86]

The idea to create brain tissue on a dish from which we can learn about how the brain
functions, is a challenging one. However, there are significant attractive benefits which completely
outweigh the challenges and risks involved in this study. The value of a lab created brain tissue on
a dish using a patient’s own stem cells is immense, including in vitro modelling and regenerative
medicine. First, tissues created from the patient’s mesenchymal stem cells can be potentially
transplanted back without ethical or immunological challenges. Second, such tissue on a dish
models can serve as better platforms for clinical drug testing generally performed in animals,
which sometimes have drastically different outcomes compared to human clinical trials. In
addition, a lab created brain tissue on a dish that accurately mimics actual brain tissue would be
significant for researching not only the effect of drugs, but neurodegenerative disorders like
Parkinson’s, Alzheimer’s and ALS as well. Our long-term goal is to build 3D neural tissues on a
dish that can capture in vivo neuronal functions and be useful as neural tissue on a dish for drug
testing.
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Chapter 3: Attenuating neurotoxicity of stainless steel used as a material for
DBS, by surface modification with Graphene-oxide
Graphene-based materials, including multilayered graphene, graphene nanosheets,
graphene oxide and reduced graphene oxide have been extensively utilized in electronics and
energy storage/conversion systems [87]. However, an increasing interest in the field of
regenerative medicine has emerged to develop nanostructured materials such as Graphene-based
substrates to be used as smart interfaces for cellular studies and regenerative medicine [80, 88, 89].
This is because, nanotextured materials are believed to provide a unique physical framework,
comparable to natural ECM, for cell culture [89]. So, in the field of tissue engineering, Graphenebased materials could be a promising candidate for novel scaffolds as they incorporate
topographical, chemical and electrical cues in the same scaffold to provide an environment for
tissue regeneration that is superior to conventional inert biomaterials [90]. Furthermore, Graphene
is highly biocompatible, has low toxicity, and superior mechanical characteristics [87]. Graphenebased substrates have been recently reported to be used in bone tissue engineering [53, 89], cardiac
tissue engineering [91], stem cell culture [80, 92, 93] and in neural tissue engineering as well [60,
79, 91, 93].
Inert materials such as platinum (Pt) is used for making neural electrodes which however
are usually not cost effective [94]. Further these Pt electrodes require nano-textured specialized
coatings for optimized performance which further increases fabrication and processing cost [94].
Therefore, there is a need for a novel low-cost coating material which will confer biocompatibility,
electrochemical performance, and sustainability for application in neural interface devices. In an
attempt to design a chemically and structurally stable robust electrode for chronic neural
stimulation, Depan and Misra fabricated a hybrid of conducting polymer (poly(3,4ethylenedioxythiophene) (PEDOT) and carbon nanotubes (CNTs). The PEDOT-CNT hybrid
nanostructured composite coating on the SS electrodes provided biocompatibility, neuronal
adhesion, neuronal outgrowth and high charge injection capacity [95]. Others reported,
poly(ethylene

glycol)-poly(ε-caprolactone)

(PEGPCL)
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hydrogel–poly(ε-caprolactone)

neurotrophin-eluting hydrogel–electrospun fiber composite coatings for multi-electrode arrays
which enhanced long-term device performance and function [96]. However, inclusion of a growth
factor and polymer has its own challenges in terms of cost and manufacturing burden, and limited
life-span of the growth factor incorporated. So a single component coating based on a polymerfree approach would be ideal for such applications to avoid toxicity associated with polymers [97].
Thus, in this study we aimed to develop graphene oxide (GO) as a novel polymer-free,
biocompatible and strongly adherent coating on 316L SS implant surfaces for neuronal cell culture
applications.

Figure 3.1: Some members of graphene family, shown in (a) Few-layered graphene, (b)
graphene nanosheet, (c) graphene oxide, and (d) reduced graphene oxide (rGO) [98]
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Graphene Oxide (GO) sheets are monolayers of carbon atoms that have oxygen atoms, OH groups and –COOH groups attached forming dense and unique honeycomb structures [99]
with applications in biomedical field [49-51, 56, 100-105]. These functional groups enable GO to
be readily dispersed in water [106]. Some members of graphene family is shown in Figure 3.1,
such as few-layered graphene, graphene nanosheet, graphene oxide, and reduced graphene oxide
(rGO) [80]. The aim of this study was to culture SHSY-5Y cells [59] to show cell adhesion,
proliferation and decreased expression of ROS signaling indicative of the mitochondrial stress in
neurons affected by PD, atop Graphene-oxide coated SS meshes (Figure 3.2).

Figure 3.2: SHSY-5Y neuroblastoma cells grown on graphene oxide coated stainless steel mesh

GO was immobilized onto 316L SS surfaces using a carbodiimide reaction by surface
treatment with (3-amminopropyl)triethoxysilane (APTES) [48]. GO coated 316L SS surfaces were
prepared, characterized and used to culture SHSY-5Y neuroblastoma cells [107] to assess the
overall biocompatibility of the modified substrate. Further this method of GO-coating can be
adapted to other metallic implants where the development of such protective and biocompatible
coatings is essential [55, 108]. Results from this study showed that GO-coated SS neural electrodes
(Figure 3.2).
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3.1 Materials and methods
Graphite

flakes

(~150

µm),

APTES

(99%),

1-(3-Dimethylaminopropyl)-1’-

ethylcarbodiimide hydrochloride (EDC), N-Hydroxysuccinimide (98%) (NHS), Atto 495 NHS
ester, was obtained from Sigma-Aldrich (St. Louis, MO, USA). 0.25% Trypsin/EDTA and
Phosphate Buffered Saline (PBS, 1X) was obtained from Sigma. 316L SS wire cloth mesh (200 x
200 Super-Corrosion Resistant type 316L SS Wire Cloth, 0.0016” Wire Diameter, 46% open area,
McMaster-Carr, Los Angeles, CA, USA) was used to mimic surgical grade 316L SS implant
surfaces. Solid strips of the same material (316L SS, thickness 0.015”, width 1” and length 24”;
McMaster-Carr) were used for contact angle, nanoindentation and film thickness measurements.
3.1.1 Preparation and characterization of GO
GO was prepared by a modified Hummer’s method as done previously [106, 109, 110].
Briefly, a 9:1 mixture of sulphuric acid/ phosphoric acid (H2SO4/H3PO4) was added to a mixture
of graphite flakes and potassium permanganate (KMnO4). The reaction was then heated to 500C
with stirring for 12 hr, and consecutively cooled and poured onto ice with 30% hydrogen peroxide
(H2O2). The mixture was sifted and filtered; it was later centrifuged and the supernatant was
decanted away. The remaining solid GO was washed consecutively with Milli-Q water, 30% H2O2,
and ethanol (C2H6O); for each wash, the mixture was again sifted and filtered. After multiple
washes, the remaining material was coagulated with ether (C2H5)2O and the resulting suspension
was filtered. The final solid product was freeze-dried under vacuum overnight. All chemicals used
in the in-house synthesis of GO was procured from Thermo Fisher Scientific, Hampton, NH, USA.
FTIR analysis: Fourier transform infrared spectroscopy (FTIR) was used to reveal
information about the molecular structure of GO prepared in-house in comparison with published
literature. Attenuated total reflectance (ATR)-FTIR spectra of a representative GO sample was
acquired using a Perkin-Elmer, Spectrum 100, Universal ATR Sampling Accessory within the
range of 650-3650 cm-1 in transmittance mode [111]. Spectral manipulations were performed using
the spectral analysis software GRAMS/32 (Galactic Industries Corp., Salem, NH, USA). External
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reflection FTIR was recorded on a Specac grazing angle accessory using an s-polarized beam at
an angle of incidence of 400 and a mercury cadmium telluride (MCT/A) detector. A piranha-treated
silicon wafer was used as the background.
3.1.2 Stainless Steel mesh treatment prior to GO immobilization
Surface modification was performed on the 316L SS meshes as follows. The mesh was cut
into 2 cm  1 cm pieces and sonicated in acetone for 20 min followed by air drying and consecutive
heating (2500C, 1 hr). The pristine cleaned 316L SS meshes were denoted as NHT (no heat
treatment), and the heated ones as HT (heat treated) respectively.
316L SS silanization with APTES: For modifying the 316L SS surfaces to promote GO
immobilization, it was necessary to covalently introduce a layer of functional silane groups onto
the surfaces. To enable this reaction, all samples were submerged in a 10% v/v solution of
APTES/Xylene (Sigma) with continuous stirring for 24 hr to facilitate the carboxyl (-COOH)
groups of the GO to covalently bond to the amine (-NH2) groups.
3.1.3 GO immobilization and retention
Atto 495 NHS-ester dye solution was made by adding 5 µl of the dye solution in DMSO
(2 mg/ml) to 95 µl of bicarbonate buffer (0.1 M, pH 8.3). 100 µl of this prepared solution was laid
onto each mesh treated with APTES to confirm the attachment of amine groups and incubated at
room temp for upto 2 hr after which they were imaged using a fluorescence microscope (Nikon
Eclipse Ti, Nikon Instruments Inc., Melville, NY, USA). Fluorescence and bright field images
were acquired and later merged with identical parameters using ImageJ.
Upon confirmation of the amine groups on the 316L SS meshes, a saturated solution of 2
mg/ml of GO/Milli-Q water was made to coat all samples by eliciting a carbodiimide reaction
using the crosslinking agents EDC and NHS [112]. Samples were submerged in 10 ml of the
GO/Milli-Q water solution, 0.8 grams of EDC and 1.2 mg of NHS were added at room temperature
(250C) with vigorous stirring for 24 hr. The GO-coated meshes were then heated in the oven
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(2500C, 1 hr) to stabilize and bind the GO coating with underlying substrate. All chemicals used
in this step were procured from Sigma.
3.1.4 Characterization of the GO-coating
XRD for confirmation of GO-coating deposition
To investigate the efficacy of the coating and the phase assemblage of the GO and the
APTES coated 316L SS strips, samples were examined by X-ray diffraction (XRD). For the XRD,
the samples were scanned using an X-ray of Cu source (CuKα, wavelength: 1.54056 Å) for a 2
theta range from 5° to 90° at a scanning rate of 2°/min with an increment (step size) of 0.05°. The
XRD machine (D8 Discover, Bruker’s diffractometer, Germany) was operated in locked-coupled
mode at 40 kV voltage and 40 mA currents.
SEM analysis for probing morphology of GO coated surfaces
To image the morphology of the deposited GO-film, scanning electron microscopy (SEM) was
used. Samples were visualized using SEM (S-4800, Hitachi, Japan) at voltages of 5KV.
Measurement of contact angle
For measuring contact angles, GO was deposited onto 316L SS strips using similar
immobilization procedures as used for the meshes. Water contact angles of the GO-coated surfaces
were measured at room temperature and humidity using a standard goniometer (Model 250-F4,
Ramé-hart, Succasunna, NJ, USA) based on the sessile drop method. For each value reported, the
mean and standard deviation of at least 10 measurements from the same sample surface were
recorded. For each case, 2 representative samples were prepared and analysed.
Estimation of coating thickness
For measuring GO-coating thickness, GO was immobilized onto 316L SS strips using
similar procedures as used for the 316L SS meshes. Cross section of the GO-coated samples was
visualized using SEM (Hitachi TM-1000 Tabletop Microscope, Tokyo, Japan) at 1000× to 5000×
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magnification. Acquired images were analyzed using ImageJ (NIH) to calculate average thickness
of the deposited GO-coatings.
Nanoindentation for mechanical analysis
A dynamic nanoindentor (TI-750H, Hysitron Inc. MN, USA) with a diamond tip of
diameter of 200 nm was used for the indentation of the GO coating. Furthermore, hardness and
elastic modulus were calculated using area under the loading and unloading curve i.e. plastic and
elastic work of the indentation, respectively. The value of total work of indentation (a sum of
plastic and elastic work) was substituted in the following equation to calculate the hardness of the
GO coating [113].

kPm3
H=
......................(1)
9Wt 2
where, k is a constant equal to 0.0408 (for a three-sided Berkovich pyramidal indenter). Pm
and Wt, are the maximum load and total work of indentation.
The standard method to measure the elastic modulus of the coating is by the analysis of the
unloading curve. This is due to the fact that even for a plastic deformation during loading, the
initial part of the unloading curve exhibits the elastic nature of the material. Therefore, slope of
initial part of unloading curve can be used to calculate the elastic modulus of the material using
following equation [114, 115].

1 − i2
1
1 − 2
=(
)+(
)....................(2)
Er
E
Ei
where, Er, E, and Ei are the reduced elastic modulus, elastic modulus of the substrate i.e.
graphene oxide coating, and elastic modulus of a diamond indenter (= 1141 GPa) [114]. ν and νi,
are the Poisson ratio of the graphene oxide (= 0.165 [116]) and the indenter (0.07 [114]).
The reduced elastic modulus can be calculated using following relation [114, 117],
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Er =

 Smax
....................(3)
2
A

where, Smax and A are the slope of the unloading at the starting point i.e. at the point of
maximum loading and the projected area of indentation. The projected area of indentation is
defined in terms of contact depth, hc and can be expressed as [114],

hc = hmax − 

Pmax
....................(4)
Smax

where,  is a constant that depends on the geometry of the indenter and for a sharp
Berkovich indenter this value is 0.75 [117]. Therefore, for the present case of nano-indentation,
equation 4 was rewritten as,

hc = hmax − 0.75

Pmax
....................(5)
Smax

It is already known from the load-displacement curve that hc < hmax [117]. The contact area
of the indentation is a function of the contact depth (hc) i.e. A = A(hc) [114] and for a perfectly
sharp Berkovich indenter,

A(h c ) = 24.5 h c2 .

Therefore, A in equation 3 was replaced with hc to calculate the elastic modulus of the
coating “E” using equation 2. Modified equation 3 shown in 6 was used to estimate Elastic
Modulus of the deposited GO coatings onto SS substrates.

Er =

 Smax
....................(6)
2 4.95hc
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3.1.5 Cell culture on GO coated surfaces
Adhesion and proliferation of SHSY-5Y neuroblastoma cells atop GO-coated surfaces
In preparation for cell culture, the precut meshes including bare, APTES-treated and GOcoated were washed first in 70% ethanol, followed by PBS (1X) and air dried under a sterile
laminar flow hood. After drying, samples were transferred to wells (one mesh/ well) in a 24 well
plate (Corning, NY, USA). SHSY-5Y cells, a generous gift from Dr. Mahesh Narayan from
Chemistry department at UTEP were seeded atop these meshes following procedures described.
SHSY-5Y is used as a model of in vitro neurodegenerative disease studies because it has
biochemical properties of human neurons in vivo [107]. Further, since these cells are tumour
derived, they have the ability to continuously grow and divide [107]. The cells can be differentiated
to provide mature neuron-like phenotype [107].
SHSY-5Y cells were grown in DMEM-F12 (1:1; Gibco, Thermo Fisher Scientific),
supplemented with 10% heat inactivated FBS (Gibco), 2 mM L-glutamine, 100U/ml penicillin and
100 mg/ml streptomycin all from Gibco. Prior to the mesh experiment, the cells were cultured and
stabilized for several passages at 37°C, 5% CO2. Confluent T-25 flasks of SHSY-5Y cells were
trypsinized and extracted for further experiments.
Pre-cleaned bare, APTES treated and GO-coated 316L SS meshes were further cut into 8
mm  8 mm (n=3 for each case) and were placed into the media per well of a 24 well plate. Then
the cells were added to these respective wells at a density of 10,000 cells/well with 2 mL of media
per well. The seeded cells on meshes in wells were then incubated (37°C, 5% CO2) for a period of
up to 72 hr.
After 72 hr, cells at the bottom of the wells were stained using DAPI (Vector labs,
Burlingame, CA, USA) and Ethidium homodimer-1 (Dead cell stain, Invitrogen, Thermo Fisher
Scientific) and imaged using an inverted fluorescence microscope (ZEISS Axio Observer, ZEISS,
NY, USA).
On the other hand, cell proliferation on the meshes was estimated as described. Meshes
seeded with cells were carefully transferred to unused wells, gently rinsed with PBS, overlaid with
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1 mL of 0.25% trypsin-EDTA per well and incubated at 37°C for 10 min. Extracted cells were
pelleted by centrifugation, and counted using a hemocytometer throughout the entire culture period
after 72 hr of culture following published procedures [118]. Similarly, cells that adhered to the
plastic wells for the respective mesh samples were also trypsin-extracted and estimated after 72 hr
of culture. Mean values obtained by averaging values from at least 3 samples per case were
reported for cells adhered onto plastic wells and mesh surfaces respectively for each case reported,
in comparison to controls (plastic only). All cell culture experiments were repeated twice (n = 3
for each experiment).
En-face images of the meshes seeded with cells were acquired using SEM following
published procedures to confirm cell adhesion onto the meshes [119]. For sample preparation, cells
on meshes were histologically fixed using 4% paraformaldehyde (Sigma, 4°C, overnite), and then
dried under a constant laminar air-flow in a fume hood. Dried samples were coated with gold (2–
3 min) in a sputter coater (Quorum EMS150R ES, Quorum Technologies Ltd., UK) and visualized
using SEM (Hitachi TM-1000 Tabletop Microscope) at 1000× to 5000× magnification.
ROS detection and quantification
In order to establish GO’s role in modulating inflammatory responses if any, reactive
oxygen species (ROS) expression in SHSY-5Y cells cultured atop GO-coated meshes were
analyzed using immunofluorescence following published procedures [120]. Levels of ROS in
SHSY-5Y cultured in vicinity of GO-coated surfaces were assessed using conversion of nonfluorescent dihydroethidium (DHE: Sigma) to fluorescent ethidium bromide. Cells cultured in
wells along with bare uncoated 316L SS (controls) and GO-coated meshes were incubated with
DHE (10 μM) for 15 min at 37°C under dark conditions and imaged within 5-7 min. Cells cultured
in wells that did not contain any meshes served as negative controls. After 15 min of incubation,
cells were visualized using an inverted fluorescence microscope (ZEISS Axio Observer).
Statistical analysis: All samples were present in triplicate unless otherwise mentioned.
Data are expressed as the mean ± standard deviation. Student’s t-test was performed to determine
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if the averages of any two sample datasets compared were significantly different. p-values less
than 0.05 were considered significant wherever reported.
3.2 Results and Discussion
3.2.1 Silanization of bare 316L SS surfaces
To modify the inorganic surface of the 316L SS mesh to promote GO immobilization, the
initial reaction that occurred on the 316L SS mesh was for the –Si-O-Si of the silane coupling
agent (APTES) to bond to –OH groups in GO on the mesh’s surface (Figure 3.3 (I)) [112, 121].
APTES is used on an routine basis for surface coatings where silanization is needed [122].

Figure 3.3: (I) Schematic for deposition of NH2 groups on 316L SS meshes. (II)
Confirmation of NH2 groups on the 316L SS meshes. Shown in panel (A-D) are Atto 495 dyed
316L SS meshes, scale bar = 100 μm. In (A) the meshes were heat and APTES treated (denoted
as HTAPTES); (C) the pristine cleaned 316L SS meshes were not heat treated but treated with
APTES (denoted as NHTAPTES). Controls for all these treatments are shown in (B) and (D).
(III) The chemical crosslinking scheme for GO adhesion.
3.2.2 Confirmation of NH2 group immobilization
Atto 495 NHS-ester die treatment confirmed the presence of amine groups on treated
surfaces. The mesh samples which were heat treated reacted the most with APTES compared to
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non-heat-treated controls. The heat-treated samples retained the maximum amount of NH2 groups
confirmed visually compared to controls (Figure 3.3 (II)). Therefore, heat treatment was used as
an optimized prior treatment for 316L SS meshes that were then reacted with APTES to bind NH2
groups.
3.2.3 Confirmation of GO immobilization
FTIR spectra analysis revealed the structure and functional groups of the in-house
synthesized GO [123, 124] (Figure 3.4 A). The spectrum showed the presence of C=O stretching
vibration centred at 1728 cm-1, graphene sheet aromatic C=C stretching vibration at 1622 cm-1,
broad O–H stretching at 3400 cm-1, C-OH bending at 1368 cm-1, C-O stretching at 1045 cm-1, C–
OH stretching at 1222 cm-1. The presentation of oxygen-containing functional groups, such as –
COOH, –OH, epoxide, and alcoxide confirmed that the synthesized compound was GO in
consistence with other published evidences [106, 109, 121]. Also, the –COOH, –OH was reacted
completely with the –NH2 groups present on the 316L SS surface from the APTES treatment,
leading to GO-immobilization. Therefore, these GO-coatings are not expected to be thrombogenic
when developed for in vivo use [55].
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Figure 3.4: Shown in (A) is a representative FTIR spectrum of GO prepared in-house. The
chemical crosslinking scheme for GO adhesion is depicted in (B). GO coating was visually
confirmed as shown in (C) in comparison with uncoated and APTES treated 316L SS meshes.
Shown in (B) is the schematic for GO-immobilization onto 316 L SS meshes and in (C) are pristine
316 SS meshes (left), APTES-coated meshes (middle) and GO-coated meshes (right).
A saturated aqueous solution of 2 mg/ml GO was used to coat all 316L SS samples as
depicted in Figure 3.4 B. GO deposition was visually confirmed on the 316L SS meshes compared
to non-coated meshes (Figure 3.4 C). GO-coated meshes were then washed, to remove unreacted
GO and then used for further experiments.
3.2.4 Confirmation of the GO-coating
Three samples in each category including bare (uncoated) 316L SS, GO-coated 316 L SS,
and APTES coated 316L SS were analysed using XRD from which one representative spectrum
from each case was depicted (Figure 3.5). The XRD spectra of bare 316L SS revealed the presence
of diffraction peaks matching with the austenite phase with three major diffraction peaks
corresponding to 111, 200, and 220. No other phase was identified in the detection limit of the
XRD (Figure 3.5). The XRD spectra of GO coated samples confirmed the presence of signatory
diffraction peaks of GO with very low-intensity diffraction peaks corresponding to substrate
material (316L SS). In addition to this, peaks corresponding to reduced GO were also found. The
XRD of APTES coated samples confirmed the presence of diffraction peaks corresponding to SiO2
(ICDD pdf # 890735). In this case, the highest intensity diffraction peaks were of the stainlesssteel substrate. However, no other phase than SiO2 and stainless steel were noted.
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Figure 3.5: XRD of bare stainless steel, GO coated stainless steel, APTES coated stainless
steel substrates, showing the presence of GO and APTES on the substrate surface.
In both cases, for GO- and APTES-coated 316L SS (ICDD pdf # 033-0397) samples, the
absence of any other diffraction peaks except the diffraction peaks of the base material and coating
confirmed the purity and efficacy of the coating and coating-method, respectively.
In addition to GO, the presence of reduced GO can be related to the in-house synthesis of
GO which involved the oxidation of graphite [123, 124]. In the case of GO coating, the peak
corresponding to GO was of highest intensity among the other phases. This confirmed GO as the
most abundant phase in the stable coating of GO on the 316L SS substrates. However, in the case
of APTES coated samples, the coating was not very uniform, which was confirmed by the presence
of high intensity diffraction peaks of austenite phase of substrate 316L SS. To fix this issue, pristine
cleaned 316L SS samples will be polished, surface smoothness confirmed using SEM and then
APTES treated in future to promote deposition of a uniform coating of APTES.
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3.2.5 Morphology of the GO coating
SEM revealed that though the GO-coating was retained all over the 316L SS mesh surface, it
seemed non-homogenous (Figure 3.6). The junctions of the meshes seemingly showed greater
amounts of GO deposited compared to struts (Figure 3.6). We attempted to graft GO onto mesh
surfaces simply stir-coating and did not employ any special means to make the coating uniform.
In succeeding studies, we will employ means to make the GO-coating uniform on the 316L SS
surfaces using electrophoretic deposition or spin coating. Further polishing the 316L SS surfaces
prior to coating will promote uniform APTES coating which will in turn facilitate uniform
homogenous GO coating.

Figure 3.6: Representative SEM images of GO-coated meshes at various magnifications.
Nevertheless, the GO-coating appeared to possess surface-roughness on a nanoscale
(Figure 3.6). No such nano-scale roughness was noted in meshes coated with APTES or in noncoated control 316L SS substrates.
3.2.6 Surface hydrophilicity is retained after GO-coating
The surface hydrophilicity retained by the GO-coating was revealed from contact angle
investigations (Figure 3.7 A). The absorbed GO-coating decreased the contact angle to
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22.31°±3.76 in comparison to bare untreated samples (33.12°±0.75) (p=0.009). Silanized APTEScoated substrate showed an average contact angle of 61.33°±0.19. Therefore, the GO-coating
conferred hydrophilicity to the coated 316L SS substrates probably due to the nano-topographic
roughness (Figure 3.7 A).

Figure 3.7: Shown in (A) are the representative images and the results of contact angle
investigations. GO-coated surfaces maintained hydrophilicity are shown above. (B)
Representative SEM image of GO-coating on 316L SS strip.
3.2.7 GO coating thickness
For the samples analysed using SEM (Figure 3.7 B), the average thickness of the GOcoating was 11.24 ± 1.23 µm. Earlier studies have shown that a single layer of GO sheet is 0.52
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nm in thickness [125]. So, it was concluded that a multi-layered coating of GO was deposited due
to APTES treatment and GO immobilization on the 316L-SS meshes. Others investigating multilayered GO films have found these coatings to be impermeable to all gases, liquids and aggressive
chemicals thereby protecting the underlying surface from interfacing with corrosive environments
[54].
3.2.8 Hardness and Modulus of elasticity of the GO-coating
Inside complex in vivo environments, applied biomaterial coatings usually play a role in
the targeted performance of a biomaterial, such as bioactivity [126]. Therefore, apart from the
biological properties, the reliability of such biomaterial coatings can be affected by its mechanical
properties, such as hardness and elastic modulus. A technique such as nanoindentation can be used
to measure the mechanical properties of applied coatings including hardness and elastic modulus
by deforming it on a very small scale. For all GO-coated samples analyzed, the average value of
hardness was 19.950 ± 0.248 GPa and the average value of elastic modulus was 570.560 ± 25.659
GPa.
The measured value of hardness and elastic modulus of GO coating was higher than the
hardness and elastic modulus of other common implant coatings on 316L SS [123, 124, 127].
Substrate hardness plays an important role in the determining the wear and tear properties of a
material and generally, a higher hardness means a lower wear rate [128]. Therefore, on the basis
of nanoindentation results it is expected that the GO-coating will exhibit significantly lower
coefficient of friction and lower wear rate as well, when implanted in vivo. Besides, studies have
also shown that substrate stiffness, a property related to hardness and elastic modulus is an
important growth cue for neuronal outgrowth and differentiation [129]. Stiffer substrates with
enhanced elastic modulus increased cultured neuronal network activity atop these substrates as
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shown by other studies [129]. Therefore the GO-coating should be beneficial for neuronal
outgrowth, and may even be beneficial in studies to probe the behavior of diseased or damaged
Parkinson’s neurons [96].
3.2.9 Biocompatibility of the GO-coating
To determine the overall biocompatibility of the GO-coatings, SHSY-5Y cells were
cultured atop these substrates. From other published studies using these cell types, it is already
known that GO is non-cytotoxic and promotes cell adhesion and differentiation in SHSY-5Y cells
[51]. In line with these published reports, it was seen that SHSY-5Y cells adhered well onto GOcoated surfaces (Figure 3.8 A, B, C), to a greater extent than on bare or APTES coated 316L SS
surfaces (Figure 3.8 D). Cells on the GO-coated surfaces appeared to express a mature neuronal
morphology and phenotype (Figure 3.8 A). Cells attached and grew on both the plastic wells and
the meshes (Figure 3.8 D), however total number of proliferating cells at the end of culture was
much lesser in wells that contained bare and APTES-coated meshes in comparison to GO-coated
meshes or plastic well controls (Figure 3.8 D). When compared within wells with meshes, cells
adhered and grew significantly more on GO-coated meshes in comparison with bare (p=0.001)
and APTES-coated (p=0.006) meshes (Figure 3.8 D). These results implied that GO-coatings
enhanced SHSY-5Y cell adhesion and proliferation thereby improving the functionality and
behaviour of these cells when seeded on GO. On the other hand, cells that were cultured in the
vicinity of the meshes including bare, APTES- and GO-coated showed maximum number of dead
cells in wells that contained the bare non-coated meshes, in comparison to the other cases (Figure
3.9). This result further supported the fact that GO was not cytotoxic.
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Figure 3.8: Representative SEM images of SH5YSY cells grown atop GO-coated meshes
in (A) (B) and (C). Depicted scale bars are a 100 µm. (D) Confirmation of cell proliferation on
GO-coated meshes. Significantly greater no. of viable proliferating cells were detected on GOcoated meshes after 72 hours of culture compared with bare and APTES-coated meshes.

SHSY-5Y cells cultured in the vicinity of GO-coated meshes exhibited lesser number of
cells that showed less intense red DHE fluorescence compared to cells cultured on pristine 316L
SS meshes. Therefore, culturing cells on GO-coated 316L SS meshes did not activate signalling
pathways that lead to ROS activation and cellular damage. In a study by Min Lv et al. [51], SHSY5Y cells cultured atop GO nanosheets showed no cytotoxicity associated with the GO, which
further enhanced the differentiation of SHSY-5Y induced-retinoic acid (RA) by increasing neurite
extension length and the expression of neuronal marker MAP2. Results from this study and others
[49] strongly imply a role of GO-coatings as applications for neurodegenerative diseases. Further,

38

we have shown that neuronal cell culture atop GO actually mediates ROS expression which could
lead to its application as coating material for neural implant electrodes.

Figure 3.9: Cells cultured in the vicinity of bare-316L SS (A, D), APTES-coated (B, E)
and GO-coated samples (C, F) stained using DAPI (top panel) and a dead cell stain, Ethidium
homodimer-1 (bottom panel) depicted in representative images. Maximum no. of cells appeared
dead when cultured in the vicinity of bare-316L SS samples but not the other cases. Scale bar is
100 µm.
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3.3 Conclusion
In conclusion, GO coated surfaces did not exhibit any significant in vitro toxicity for
SHSY-5Y cells and reduced their ROS expression, confirming its biocompatibility. Further, GO
coatings were found to be stable, non-reactive and added surface roughness to the implant surfaces
which permitted cell adhesion, spreading and proliferation, without inclusion of any additional
neuronal growth factors [96]. All of these characteristics make GO suitable for 316L SS
biomedical implants and devices. This study significantly advanced the existing knowledge on the
biological properties of GO-coating and its possible applications in biomedical field.
The procedure employed for making GO-coatings in this study is fairly facile, inexpensive
and less time consuming. In addition, our technique for making GO-coatings is aqueous based,
easily scalable, cost effective and allows room temperature fabrication. The finding of these results
can be extended to other studies wherein such hydrophilic and corrosion defiant GO-coatings also
have immense potential as a protective shield for oxidation prone active metal surfaces.
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Chapter 4: Stem cell differentiation for targeted DA neuron transplantation
Stem cell based tissue engineering has tremendous potential of long-term restoration of all
types of tissues including skin, cardiac, bone and nerve by gene therapy [130]. Though
biocompatible metals and soft natural and synthetic polymers have been extensively used for
fabricating brain electrode and cell transplant scaffold in tissue engineering and regenerative
medicine research, graphene has shown to accelerate stem cell differentiation being mechanically
robust, biocompatible, flexible and electrically conductive. Graphene was used as a neurointerface electrode without altering or damaging signal strength or formation of scar tissue [131].

Figure 4.1: DA neuron pathway in the mid-brain [132]

Cell transplantation therapy involves culturing the undifferentiated stem cells in vitro and
then implant the cells at the brain injury site with protein, growth factors and neurotrophic factors
for direct differentiation into neuronal cells. The stem cells can be differentiated in the lab to model
different neurodegenerative disorders in a dish to investigate the disease nature and possible
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treatments before performing animal study and clinical application [133]. Figure 4.1 shows the
representative image of the DA neuron pathway in the human mid-brain [132]. In case of
neurodegenerative disease like Parkinson’s, large portion of dopamine producing cells are lost in
the mid-brain. So, artificially created neural tissue needs to be implanted to replace the larger
number of cells at the site of injury.
For this reason, dopaminergic neuron differentiated from stem cells in a 3D scaffold needs
to be implanted to mimic the actual cellular microenvironment and damaged tissue site [133].
These 3D scaffolds should have microporous structure to act as the carrier for the transplanted
cells and growth factor for differentiation. Pre-engineering living three-dimensional (3-D) neural
tissue outside the body with controlled neuroanatomical and functional characteristics promote
neuro-regeneration which can be used for the therapies of neurodegenerative diseases.
4.1 Neural tissue engineering using stem cells
Neural tissue engineering offers enormous promise in replacing damaged neural tissue and
restoring the lost function of the nervous system by implantation in the form of graft or scaffold in
both Central Nervous System (CNS) and Peripheral Nervous System (PNS). The CNS consists of
the brain and the spinal cord, while the PNS consists of nerves that originate from the brain and
spinal cord and innervate the rest of the body [134]. Tissue engineering for the peripheral nervous
system are focused on axonal regeneration inside nerve graft and for the central nervous system
are focused on cell transplantation and electrical stimulation by using cell culture techniques and
biomaterials [134].
MSC is isolated from bone marrow, adipose tissue, umbilical cord and other tissues. MSC
collected from bone marrow are also capable of differentiating into neuronal cells on tissue
engineered nanofibrous scaffolds [76]. The combination of mesenchymal stem cells and

42

biomaterial scaffolds offers a hopeful strategy for engineering functional tissues and cellular
delivery for Parkinson’s disease treatment. There is an absolute need for a scaffold for stem cell
transplantation therapy using stem cells, as stem cells have a tendency to migrate out of the injury
site to other sections of the brain and the therapy would not be effective in that case. Table 4.1
demonstrate the benefit of mesenchymal stem cell application in treating Parkinson’s disease [75].
Table 4.1: Bone-marrow derived MSC from different sources for PD treatment
MSC source

Route of MSC

Sprague-Dawley

Intrastriatal

Rats

Results

Ref.

Differentiated MSCs improved rotational [135]
behavior; partial restoration of tyramineinduced DA release in the striatum
MSCs cultured in hypoxic conditions [136]
induced an increase in striatal DA levels
and behavioral improvements

Substantia nigra

BM-MSCs

differentiated and induced [137]

behavior improvements and protection of
nigrostriatal system
Intravenous

Improvements in motor behavior and [138,
protection of TH+ fibers in the striatum and 139]
SN

Human

Intrastriatal

Improvements

in

rotation

behavior, [140]

inhibition of DA depletion in the striatum;
regeneration in striatal DAergic nerve
terminal network
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Differentiated MSCs reduced rotational [141]
behavior

Naı¨ve

MSCs

induced

neurogenesis in the subventricular zone
Femoral vein

Reduction in rotational behavior; increase [142]
in the number of TH+ neurons; inhibition of
glial activation

Substantia nigra

Differentiation into DAergic neurons in [143]
vivo; behavioral improvements

EGFP-Dark

Intranasal

Agouti rats

Neuroprotective and anti-inflammatory role [144]
of MSCs; recovery of motor function;
increased TH and DA levels in striatum and
SN; decreased apoptosis

Human

Intrastriatal

Human

Tail vein

Behavioral improvements

[145]

Reduced loss of TH+ cells; increased DA [146]
levels in striatum; decreased activation of
microglia and caspase-3 activity

Human

Tail vein

Decreased loss of TH+ cells in the SN and [147]
inhibition of microglia activation

Human

Intrastriatal

No suppression of inflammatory response; [148]
no neurogenesis
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Wistar Rat

Carotid artery

No effects on progression of neuronal [149]
damage or on motor impairment; reduced
turning behavior

Intrastriatal

Immune response to allogeneic transplanted [150]
BMMSCs

Wistar Rat

Intravenous

Prevented loss of TH+ cells in the SN; no [151]
improvements in motor activity

Autologous

Putamen

Differentiation to A9 DAergic neuron-like [152]
cells; motor function improvements

Human MSC are known to home to various sites and even cross the BBB to the CNS to
restore the levels of DA neurons. Results from the studies mentioned in Table 4.1 strongly
implied the role and potential for MSC to differentiate into DA neurons [135-152].
4.2 Biomaterials as tissue engineering scaffolds
Biomaterials configured as three-dimensional (3D) scaffold hydrogels provide stem cells
with an appropriate microenvironment in order to reproduce the functions of the damaged tissue
[78]. Natural scaffolds such as collagen, fibrin, and hyaluronic acid are generally more
biocompatible, degrade into non-toxic byproducts, and contain innate cell adhesion and signaling
elements. Synthetic scaffolds such as polylacticoglycolic acid (PLGA) or polyethylene glycol
(PEG) can be tuned to have ideal mechanical and chemical properties, are optimal for
manufacturing purposes, but formation of toxic products during polymerization and degradation
can be drawbacks. Key parameters in the design of scaffolds for stem cell transplantation are
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mechanical properties, biocompatibility, polymerization and degradation rate, and adhesion site
availability. It has been shown that stem cell behavior can be directed by the stiffness of the
substrate in vitro [78].
The various components that comprise the Extracellular matrix (ECM) of the cells provide
a robust foundation for developing scaffolds based on natural biomaterials [78]. In addition, natural
materials tend to be biocompatible and contain sites for cellular adhesion, providing substrates for
stem cell survival, growth, and function. Injectability of these materials allows for in situ
polymerization in addition to the formation of a tight apposition with the lesion cavity, especially
in the case of stroke [78]. Modern tissue engineering is increasingly using three-dimensional
structured biomaterials in combination with stem cells as cell source, since mature cells are often
not available in sufficient amounts or quality [78, 153].
The transition from traditional two-dimensional (2D) cell culture platforms toward threedimensional (3D) systems seeks to overcome the limitations of 2D cellular models and mimic the
native cellular microenvironment. Such 3D tissue culture platforms provide the opportunity for
further understanding of structure−function relationships and tissue pathophysiology; as well as
facilitate the development of novel regenerative medical treatments to help restore and strengthen
lost functionality. A critical challenge of this evolution has been the development of biocompatible
scaffolding to simulate the natural extracellular matrix (ECM). Beyond the biological materials
such as protein-based ECMs, novel engineered materials offer improved functionality and
customization for localized chemical delivery and bioactivity monitoring. Among these materials,
graphene has become an excellent alternative because of physical, electrical, and mechanical
properties [154].
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In biomedical applications, 3D macroscopic structure is needed as 2D graphene often does
not meet the mass and volume requirements. 3D graphene foam has high specific surface area due
to the porous structure, but low mechanical strength. The powder metallurgy (Nickel) template
free standing GF shows better mechanical strength. The specific surface area can be measured by
measuring N adsorption-desorption by BET method with BET surface analyzer and pore size was
determined by BJH method with pore size analyzer [155].
Implantation of patient specific-stem cell-derived dopaminergic (DA) neurons and their
regenerative responses might provide a path to functional recovery in neurodegenerative disease
and brain injury [156]. The value of a lab created DA neuronal tissue in a dish using a patient’s
own stem cells is immense, including in vitro modeling and regenerative medicine [157]. First,
tissues created from the patient’s own mesenchymal stem cells can be potentially transplanted back
without ethical or immunological challenges [157, 158]. Second such tissue on a dish models can
serve as better platforms for clinical drug testing generally performed in animals, which sometimes
have drastically different outcomes compared to clinical trials [158]. In addition, a lab created
tissue on a dish that accurately mimics actual brain tissue would be significant for researching not
only the effect of drugs but neurodegenerative disorders like Parkinson’s, Alzheimer’s and ALS
(Amyotrophic Lateral Sclerosis) as well [8, 159-164]. So, our long-term goal is to culture 3D, DAneuronal tissues on a dish that can capture in vivo neuronal functions and can be useful as tissueon-a-chip for drug cytotoxicity studies. At the same time, we are interested in providing an optimal
3D scaffold for evaluating the adhesion, culture, and differentiation of mesenchymal stem cells
into DA neurons, for use as a platform for neural tissue engineering applications, such as for the
treatment for neurodegenerative disorders.
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4.3 MSC differentiation into DA neuron in 3D graphene scaffold
Biomimetic 3D scaffolds are preferred tools for culturing neurons as they provide defined
mechanical and physicochemical properties with an interconnected porous structure that can
enable a higher or more complex organization than traditional two-dimensional monolayer
conditions [165]. Changes in the internal geometry and mechanical properties of such 3D scaffolds
can impact cell behavior including survival, growth, and cell fate choice [165]. Other specific
characteristics required of scaffolds for culturing neurons are electro-conductivity and nanoarchitecture, both of which are offered by Graphene [60, 166]. Graphene is composed of a single
layer of carbon atoms arranged in a two-dimensional honeycomb lattice [167]. Other than being
routinely used for electrical, optical and thermal applications, studies also proposed the potential
of graphene for biomedical applications [167]. Graphene can be used as an optimized scaffold for
cell-culture, tissue engineering, and regenerative medicine applications [60]. Published works of
others have shown that graphene substrates can support the adhesion, proliferation and
differentiation of mesenchymal stem cells (MSC), induced pluripotent stem cells (iPSC), and other
mammalian cells [60]. Specifically for neural tissue regeneration, graphene has demonstrated the
ability to perform as an effective platform compatible with neural cells or their precursors [60],
and promoted neurogenesis, as assessed by neurite sprouting and neural network formation [166,
168]. Human MSC growth, followed by neural differentiation was also supported by a monolayer
of graphene substrate [169]. Further, the capability of graphene substrates to electrically stimulate
differentiated neuronal cells was demonstrated [170]. Our recent published work showed that
Graphene-oxide coatings enhanced the survival and proliferation of SH5YSY neuronal cells [59].
Based on these reports, we hypothesized that Graphene-based substrates may be a
promising scaffold material for neural tissue engineering. In this study, our objective was to utilize
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a commercially available 3D Graphene scaffold termed as ‘Graphene foam’ (GF) for culturing
mouse MSC and differentiating them into DA neurons. We hypothesized that these MSCdifferentiated DA neurons when cultured in a 3D scaffold, will more closely exhibit morphologies,
functions and other necessary characteristics of in vivo DA neuronal tissues, compared to 2D
culture or monolayer substrates. To culture cells on the hydrophobic Graphene substrates [125],
they need to be coated with proteins, such as Laminin [154, 171] to promote hydrophilicity and
cell adhesion onto these surfaces. On the other hand, collagen coating is a well-established
procedure for cell culture and collagen coatings when applied to Graphene-based substrates were
shown to not interfere with the porous structure of Graphene [172]. So, we opted to coat the
hydrophobic graphene-foams using collagen as it would lead to the formation of a hydrophilic,
porous and conductive scaffold ideal for neuron culture.

Figure 4.2: Mesenchymal stem cell (MSC) was differentiated into dopaminergic (DA)
neuron on top of collagen coated graphene foam scaffold
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Figure 4.2 shows the steps that we followed to fabricate the 3D graphene scaffold to
differentiate MSC into DA neurons. This work will significantly contribute by enabling a platform
that will allow us to study interactions between healthy DA neurons, their synaptic
communications, and identify mechanisms involved in DA neuron apoptosis during injury and
disease. As studying DA neuronal cell death in human brains is extremely difficult and invasive,
development of such in vitro 3D models of DA neurons would make it feasible to probe cellular
and molecular mechanisms of neurodegenerative disorders and implement novel therapeutic
strategies. This study is innovative as the technique might be adaptable for engineering other 3D
tissue models from different stem cell types.

4.3.1 Preparation of the graphene-foam and collagen coating
3D Multilayer Freestanding Graphene Foams (GF) (2 X 2) were purchased from
Graphene Supermarket (Calverton, NY). For cleaning, these foams were washed with 70%
ethanol, followed by UV exposure for 30 min in a laminar sterile flow hood. Using a sterile biopsy
punch (~1 mm deep, 8 mm diameter) samples were prepared for further processing and
experimentation. These pristine GF discs were collagen coated [173] and crosslinked with genipin
[174], using published guidelines. For coating of the GF, collagen from Bovine Achilles Tendon
(Sigma-Aldrich) at a concentration of 9 mg/ml in 0.2 M acetic acid was used for extraction of acidsoluble collagen (for 24 hr @ 200 rpm). The extract was analyzed using Fourier Transform Infrared
Spectroscopy (FTIR) to confirm the presence of collagen, in comparison with existing literature.
After collagen coating, GF samples were incubated at 37°C for 24 hr in Genipin (stock
solution of 100 mM in DMSO, Enzo Life Sciences), prepared using a ratio of 1:100 of Genipin in
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1X PBS to further crosslink the collagen atop the GF [175]. After 24 hr, the crosslinked collagen
coated GF samples were washed using sterile 1X PBS (Sigma-Aldrich) for 3 times prior to
consecutive experiments.
To confirm the crosslinking of the collagen using Genipin atop the GF using the procedure
described above [175], rheometry was used to compare the properties of the non-crosslinked
versus the crosslinked collagen samples. Collagen gels for rheometry were formed as described
previously [176] and cut using a biopsy punch (~1 mm deep, 8 mm diameter). The gels were preswollen in 1X PBS before testing. Oscillatory shear stress rheometry was performed (1% strain,
0.5 – 50 Hz) using an Anton-Paar MCR101 rheometer (Anton-Paar, Graz, Austria) with an 8 mm
parallel plate geometry. The strain and frequency range were analyzed within the linear
viscoelastic range of the gels by frequency sweeps. Elastic modulus was calculated through
complex shear modulus with storage and loss modulus, and complex viscosity was measured at
1.76 - 1.99 Hz for all samples, as done earlier [176].
4.3.2 Experimental analysis
Scanning Electron Microscopy (SEM)
Images of the surfaces of the pristine GF were acquired using SEM (S-4800, Hitachi,
Japan) at voltages of 10 kV. For imaging of the collagen-coated GF, samples were air-dried and
coated with Graphite Spray (Electron Microscopy Sciences, Hatfield, PA) to minimize charging
during observation and imaged at voltages of 1 kV.
Raman Analysis
The pristine GF and collagen-coated GF was characterized by Raman spectroscopy to
study the vibrational properties of the material to provide information on molecular vibrations and
crystal structures.
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X-Ray Diffraction Analysis
For the phase analysis, the samples were air-dried prior to X-ray diffraction (XRD, D8
Discover, Bruker’s diffractometer, Karlsruhe, Germany). XRD was carried out at 40 kV voltage
and 40 mA currents with CuKα wavelength (1.54056 Å) and 2θ ranges from 10° to 50° at a
scanning rate of 3°/min with a step size of 0.1°.
Electrical characterization
To explore the electrical transport properties of GF and collagen-coated GF, a two-probe
measurement was conducted using a Micromanipulator (Carson City, Nevada). In the
measurements, tungsten probes were used to measure the I-V (Current vs. Voltage) curve when a
bias voltage of 0 to 3 V was applied.

Biocompatibility testing
Strain C57BL/6 Mouse Mesenchymal Stem Cells (mouse MSC, catalog #: MUBMX01001) and Mouse Mesenchymal Stem Cell Growth Medium (complete growth medium, catalog
#: MUXMX-90011) were purchased from Cyagen (Santa Clara, CA, USA). The cells were grown
and stabilized for at least 8 passages before being used in further experiments. Prior to being
introduced into the 3D scaffolds, cells were labeled with PKH26 red fluorescent dye (Sigma)
following manufacturer’s protocols. These labeled mouse MSC were seeded atop collagen coatedGF, or controls (tissue culture plastic wells) in a density of 1 X 106 cells/ml placed within 24 wells
of a tissue culture well plate (Fisher-Scientific) and cultured for at least 72 hr (37°C, 5% CO2).
Confirmation of cell retention within the collagen coated-GF was done using SEM (as described
before) and inverted confocal fluorescence microscopy (ZEISS LSM 700 Confocal, Germany).
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Flow Cytometry (FACS) analysis
To estimate cell proliferation and overall biocompatibility of the collagen coated-GF,
mouse MSC were pre-stained using Cell Trace Violet, proliferation kit (Invitrogen, Carlsbad, CA,
USA) using manufacturer’s protocols. These pre-stained cells were seeded (4 X 106 cells/ml) atop
3D collagen coated-GF, 2D tissue culture plastic wells (controls) and cultured for 24 hr, and 48 hr
respectively (37°C, 5% CO2). After 24- and 48-hr, samples were treated using Trypsin-EDTA
(0.25%, phenol red) (ThermoFisher, Waltham, MA), cells were detached, extracted and processed
for flow cytometry (FACS). Extracted cells were fixed and processed further for FACS (Beckman
Coulter Gallios Flow Cytometer, Brea, CA, USA) using excitation and emission wavelengths of
405 and 450 nm respectively. Pre-stained cells grown in plastic Petri dishes for 72 hr served as
positive controls. Negative controls included non-stained cells cultured on plastic Petri dishes for
72 hr.
Differentiation of mouse MSC into DA neurons
Mouse MSC used for the differentiation were cultured and passaged as described below.
Prior to cell seeding, T-75 culture flasks were coated with 0.1% gelatin (Sigma Aldrich, St. Louis,
MO, USA) and incubated (37°C for 1 hr). After this, the cell suspension in complete culture
medium was transferred to a gelatin-coated T-75 flask and incubated for 1 hr (37°C, 5% CO2 and
95% RH). Prior to cell culture, the gelatin solution used for coating of the flasks was aspirated.
After 70% confluency in culture was attained, cells were trypsinized and passaged for further
experiments.
For induction of differentiation of mouse MSC into DA neurons, 2 types of 3D scaffolds
were used. These included the collagen coated-GF and collagen gels only. For the preparation of
collagen gels, the collagen extract was loaded into a 10 ml syringe (BD Biosciences, San Jose,
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CA) and ejected into a 24 well for deposition and settling. Once a smooth surface of the deposited
collagen was observed, the wells were incubated with the genipin solution for crosslinking (as
described earlier). After crosslinking was completed, uniform size disc-shaped samples for both
collagen coated-GF and collagen gels only were punched out using a biopsy punch (~1 mm deep,
8 mm diameter).
For the differentiation of mouse MSC into DA neurons atop 3D scaffolds or 2D culture
plastic, published protocols were followed [177]. For the differentiation, initial cell seeding density
of mouse MSC in the 2D plastic wells was maintained at 3 X 105 cells/ml based on published
guidelines [58], and for the 3D scaffolds, cell density was adjusted based on the total volume of
the scaffolds (6 X 106 cells/ml). Briefly, passaged mouse MSC cells were seeded on poly-D-lysine
(BD Biosciences) coated dishes (using complete growth media for mouse MSC) and after 24 hr
the culture medium was replaced using Neurobasal Media (Catalog number: 21103049; Thermo
Fisher-Scientific). At this point, Sonic hedgehog (SHH, R & D Systems, Minneapolis, MI),
Fibroblast growth factor (FGF8, R & D Systems), Basic fibroblast growth factor (BFGF, R & D
Systems) were added and incubated for 6 days. After this, Brain-derived neurotrophic factor
(BDNF, Cell Sciences, Canton, MA) was added to the culture and further incubated for 3 days.
After a total of 9 days of culture, to confirm the differentiation of MSC into DA neurons, the cellseeded scaffolds and controls were fixed with 4% paraformaldehyde (Sigma) for 15 min (25°C)
and then permeabilized with 0.2% Triton X-100/PBS for 1 hr. After blocking with 1% normal goat
serum (NGS/PBS, Sigma) for 1 hr at room temperature, the samples were incubated with a mouse
monoclonal antibody to -III tubulin [5.2F] for location of -III Tubulin and for detection of
Vimentin, the samples were incubated with Vimentin mouse monoclonal antibody (24 hr at 4°C)
followed by a goat polyclonal secondary antibody to mouse IgG1-heavy chain (FITC) (Abcam,
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Cambridge, UK) (2 hr at 25°C). For detection of TH, the samples were incubated with a purified
rabbit monoclonal IgG antibody to TH and for detection of NeuN, the samples were incubated
with NeuN rabbit polyoclonal antibody (24 hr at 4°C) followed by a goat anti-rabbit IgG secondary
antibody, Alexa Fluor 488 conjugate (2 hr at 25°C) at a dilution of 1:1000 for in the dark. The
samples were then washed with 1X PBS thrice and mounted using Fluoromount-G with DAPI
(Thermo Fisher-Scientific) and imaged using a confocal fluorescence microscopy (Olympus IX81
inverted fluorescence motorized microscope, Japan).
As a control, for the differentiation of mouse MSC into DA neurons, we chose to induce
differentiation in human MSC alongside (online supplement) the mouse MSC. This was important
to confirm the validity of the differentiation induction protocol in mouse MSC, compared to the
human MSC and also contrast the response of both cell types to the same differentiation protocol.
Axonal extensions on proximal and distal sides of differentiated neurons in collagen
coated-GF and in collagen was measured by calculating the axonal outgrowth length, visualized
with -III tubulin or NeuN and analyzed using ImageJ software [178]. Final results were expressed
as average length of neurite extensions in collagen coated-GF and in collagen, normalized with
controls (cells differentiated in 2D wells).
Statistical analysis: All samples were present in triplicate unless otherwise mentioned. Numerical
data are expressed as the mean ± standard deviation. Microsoft Excel Student’s t-test was
performed to determine if the averages of any two sample datasets compared were significantly
different. p-values less than 0.05 were considered significant.
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4.4 Results and Discussion
As shown in Figure 4.3 A, the pristine GF was extremely light, hydrophobic and fragile
during routine handling. For this reason, the pristine foams had to be coated with collagen to retain
hydrophilicity, increase their weight and improve their handling characteristics (Figure 4.3 B, C).

Figure 4.3: (A) Pristine Graphene foam floating in PBS in a 60 X 15 mm Petri dish. (B)
Graphene foam being coated with Collagen. (C) Graphene foam after Collagen coating was
crosslinked with Genipin (100 X 15 mm Petri dish shown in (B) and (C)).
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Figure 4.4: (A) FTIR spectra of collagen extract. Shown in (B) and (C) are Rheology
analysis of the non-crosslinked and crosslinked collagen, respectively. Characteristic datasets were
obtained from disc shaped (8 mm) samples of collagen, in both cases.
The FTIR spectra of acid soluble collagen extract are shown in Figure 4.4 A. A free N-H
stretching vibration was evident in the range of 3400–3440 cm−1. The hydrogen bonding of the NH group of the peptide was evident at 3300 cm−1 [179]. The amide-I band was evident around 1650
cm−1, fitting well the range of 1625–1690 cm−1 for general amide-I bands position. The amide-II
band was detected around 1540 cm−1, compared to the normal absorption range of the amide-II
bands position (1550–1600 cm−1). This was due to the existence of hydrogen bonds in collagen
[179]. The helical structure of the collagen was confirmed from IR absorption ratio between 1235
(amide-III) and 1450 bands, which was approximately equal to each preparation. The results
showed the helical structure of collagens were kept well. In addition, a strong C-H stretching
vibration was evident at 2854 cm−1 and at 1745 cm−1.
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It was essential to confirm the crosslinking of the collagen atop the GF by a secondary
technique, other than by visual confirmation (Figure 4.3 C). Therefore, rheometric analysis of the
non-crosslinked and crosslinked collagen samples was done, from which it was determined that
the strain and frequency range were within the linear viscoelastic range of the gels by amplitude
and frequency sweeps (Figure 4.4 B, C). We were able to generate crosslinked gels of significantly
enhanced elastic modulus ~ 5.0 KPa compared to the non-crosslinked samples which revealed an
elastic modulus ~ 1.78 KPa. Additionally, crosslinking increased the complex viscosity of the gels
from 277–2610 Pa-s.
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Figure 4.5: Material characterization of Graphene foam, coated with Collagen coating and
crosslinked with Genipin. (A) Scanning Electron Microscopy (SEM). (B) Current Voltage (I-V)
characteristics. (C) Raman and (D) XRD spectra, respectively.

Figure 4.5 A showed a characteristic SEM image of a collagen coated-GF that confirmed
the deposited collagen coating, in comparison with the pristine GF. Further, it was evident that the
collagen coating did not alter the basic morphology and architecture of the GF. From the I-V
(current vs. voltage) curve, it is clear that the GF exhibits a non-linear behavior with current level
of ~ 0.10 A at 3 V, while the collagen-coated GF also exhibited a non-linear behavior but with
three orders of magnitude drop in current (~ 0.16 mA at 3 V) in Figure 4.5 B. For the collagencoated GF, the curve did not appear as smooth as the GF, as collagen is an insulator by nature
which introduces noise to the signal. From this measurement, it is clear that the collagen-coated
GF yields reasonable electrical transport compared to pristine GF which paves the way for further
electric stimulation of neuronal cells.
Figure 4.5 C demonstrates the typical Raman spectra of a collagen coated-GF using a 532
nm laser at room temperature. The Raman spectra of the 3D GF contained two major peaks near
1580 and 2700 cm-1, corresponding to the G and 2D bands of graphene. There is no major D band
in the Raman spectra of the pristine GF, which confirmed that it is almost defect-free. The
integrated intensity ratio of the G to 2D band (G/2D) indicates that the GF was primarily
multilayered graphene [180]. After coating the GF with collagen, D peak appeared near 1350 cm1

and some other peaks emerged including a minor peak at ~ 2,450 cm−1 (G′ band). The defect was

increased from 0.02 to 0.7 in collagen-coated GF which is estimated from the intensity ratio of the
D band and G band (D/G) [181]. The amide-III peak appeared at 1242 cm-1 which is a characteristic
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of the collagen (Figure 4.5 C), though the amide-I and amide-II peaks were absent in the spectra
[182]. These results confirmed the successful deposition of collagen atop 3D GF.
XRD spectra of the collagen-coated GF is shown in Figure 4.5 D. The two diffraction peaks
at 2θ = 26.5° and 2θ = 55° correspond to the (002) and (004) planes of graphene respectively
where, the intensity of the peak at 2θ = 26.5° got reduced for the collagen coating [181, 183]. The
diffraction peaks of collagen appeared corresponding to the crystallographic planes (211) and
(222) at about 2θ = 32° and 2θ = 45.3° indicating traditional mineralized collagen [184].
(A)

(B)

50 µm

Figure 4.6: Adhesion and Retention of mesenchymal stem cells cultured in collagen coatedGF shown by (A) SEM imaging and (B) Fluorescent images of PKH26 pre-stained cells within
the scaffold. Red arrows in (A) point to the cells and their extension processes.

Figure 4.6 confirmed the retention of mouse MSC within the collagen-coated GF after a
sustained in-vitro culture period. The cells appeared to grow homogenously throughout the entire
culture area and appeared to exhibit extensions to connect and network with the substrate (Figure
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4.6 A, depicted by red block arrows). This observation was confirmed by the evidence of prestained cells retained within the collagen-coated GF (Figure 4.6 B).
.

Figure 4.7: Viability and proliferation of mesenchymal stem cells in collagen coated-GF
by FACS analysis. Cells pre-stained with cell trace violet were cultured upto (A) 24 hr. and (B) 48
hr. within collagen coated-GF.

Results from FACS analysis (Figure 4.7) showed that after 24 hr of culture, 1.1% of the
total number of cells seeded had proliferated in comparison to controls (unstained, 0.3%). After
48 hr of culture, 34.9% of the cells were found to have proliferated (in comparison with 32%
proliferating cell population in positive controls). Further, the occurrence of multiple peaks (Figure
4.7 B) revealed the presence of consecutive proliferating generations of cells, confirming that the
GF was not cytotoxic and promoted mouse MSC adhesion and growth
For the first time in this study, we adopted and optimized a differentiation protocol for
induction of DA neuronal differentiation of mouse MSC based on others published protocols using
human MSC [177]. We succeeded in reducing the overall differentiation protocol duration from
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12 days to 9 days in mouse MSC, compared with human MSC. This would allow results to be
achieved rapidly compared to previously reported literature [177].

(A)

(B)

(C)

(D)

(E)

(F)

NeuN (Red) and
Vimentin (Green).
Counterstained with
DAPI for nucleus.

NeuN (Red) and βIII tubulin (Green).
Counterstained
with DAPI for
nucleus.

Neurons differentiated from mouse MSC

TH (Red) and β-III
tubulin (Green).
Counterstained
with DAPI for
nucleus.

Mouse mesenchymal stem cells (MSC)

Figure 4.8: Confirmation of differentiation of mouse mesenchymal stem cells (MSC) into a
neuronal phenotype as they stained positively for (B) β-III tubulin and NeuN. These
differentiated neurons exhibited a phenotype resembling DA neurons as they positively stained
for (D) Tyrosine Hydroxylase (TH) and β-III tubulin. Further these differentiated DA neurons
did not stain positively for (F) Vimentin. Controls consisting of undifferentiated mouse MSC did
not stain positively for (A) NeuN and β-III tubulin and (C) TH and β-III tubulin. But they stained
positively for (E) Vimentin. Scale bar is 100 µm in all images.

The confirmation of differentiation of mouse MSC into neurons, stained by the neuronal
markers, -III Tubulin [185] and NeuN [186], was clearly evident (Figure 4.8 B, F) by atypical
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neuronal cell-like morphology and extensions, in comparison with controls (Figure 4.8 A, E). It
should also be noted that these differentiated neurons expressed a phenotype resembling DA
neurons due to their positive expression and enhanced levels of TH [187], unlike their
undifferentiated controls (Figure 4.8 C and D). Although the undifferentiated mouse MSC did not
express neuron like morphology or neuronal markers (Figure 4.8 A, C, E), but stained positively
for Vimentin, a stem cell marker [188]. These results collectively confirmed the differentiation of
mouse MSC into DA neurons.
A comparison of the morphology and expression of and neuronal and dopamine producing
markers in neurons differentiated in both collagen coated-GF and collagen gels, revealed
significant differences (Figure 4.9). Cells in contact with the collagen coated-GF not only showed
enhanced expression of both neuronal markers, -III Tubulin and NeuN (Figure 4.9 B, D, F) but
also TH (Figure 4.9 D) in comparison with cells in contact with collagen gels ((Figure 4.9 A, C,
E). Comparison of normalized average neurite extension from cells differentiated in both collagen
coated-GF and collagen revealed significant differences (p = 0.002) (Figure 4.10). This result
implies that the 3D GF might be a better substrate for neuronal culture compared with collagen
gels. The images of the neuronal extensions within the 3D scaffolds corresponded to others
published images of neuronal networks [189].
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NeuN (Red) and βIII tubulin (Green).
Counterstained
with DAPI for
nucleus.

(A)

Collagen coated-GF
(B)

TH (Red) and β-III
tubulin (Green).
Counterstained
with DAPI for
nucleus.

(C)

(D)

NeuN (Red) and
Vimentin (Green).
Counterstained with
DAPI for nucleus.

Collagen

(F)

(E)

Figure 4.9: Comparison of differentiated DA neurons from mouse MSC in contact with
(A), (C), (E) collagen gels and in contact with (B), (D), (F) collagen coated-GF. Confirmation of
differentiation of mouse mesenchymal stem cells (MSC) into a neuronal phenotype resembling
DA neurons was exhibited in all cases but, cells differentiated in Graphene foam-based scaffolds
exhibited significantly longer neurite extensions than those cultured in contact with collagen.
Scale bar is 30 µm in all images.
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Although monolayer Graphene substrates have been used for MSC culture [169], it is the
GF that offers a 3D porous substrate for neural cell culture and neural regeneration as also shown
by other’s work [190]. After coating the GF with collagen, this hybrid scaffold poses as a
biocompatible, porous substrate which is effective for cell culture and differentiation. Although
several types of polymer enriched GF have been fabricated [191], this is the first time GF coated
with collagen was prepared and used for neural tissue engineering applications. In the future,
specific growth factors could be encapsulated within these scaffolds for delivery to cultured cells
for their growth or targeted differentiation [192]. As the 3D GF allows the DA neurons to maintain
their morphology and function, we envision that this neuron filled scaffold can be directly
implanted in vivo or be used for studies exploring neuronal functions in vitro, in the future.
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4.5 Conclusions
Networks of neurons (in vivo) develop via an elaborate succession of cellular events that,
when disrupted, can lead to neuron dysfunction and degeneration [84, 157, 161, 163, 170, 193202]. Injuries or disease conditions, either in the peripheral (PNS) or central (CNS), require
reconstruction through advanced regenerative medicine and/or tissue engineering approaches. In
this study, our goal was to prepare a 3D scaffold suitable for MSC adhesion, growth and
differentiation into DA neurons. We successfully prepared collagen coated-GF as 3D scaffolds for
cell culture and differentiation. The collagen coating did not alter the basic properties of the GF
but enhanced its hydrophilicity and handling characteristics at the same time. Mouse MSC adhered
and proliferated well within these scaffolds. Furthermore, these MSCs were efficiently
differentiated into DA neurons when seeded within these collagen coated-GF.
The outcomes from this study are both novel and significant because it will help reveal
interactions between healthy DA neurons and their synaptic communications. It can also help
predict mechanisms involved in injury- or disease-induced DA neuron apoptosis. Outcomes from
this study can be extended to model other networks of neurons, such as cortical neurons to study
normal and abnormal corticogenesis in the CNS [199], peripheral nerves that are involved in spinal
cord injuries [203] or even used to model diabetic neuropathy in vitro [204].
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Chapter 5: Future outlook
In this study, both materials-based and tissue engineering approaches for PD treatment was
applied. In the first experiment, GO coated 316L SS surfaces did not exhibit in vitro neurotoxicity
for SHSY-5Y cells and reduced their ROS expression, confirming its biocompatibility. Further,
GO coatings were found to be stable and non-reactive. In SEM images, we observed surface
roughness to the implant surfaces which permitted cell adhesion, spreading and proliferation,
without inclusion of any additional neuronal growth factors [96]. To make the coating uniform,
enhanced coating techniques can be applied such as, spin coating [205] or electrophoretic
deposition [39]. The procedure employed for making GO-coatings in this study is simple,
inexpensive and less time consuming.
In the second experiment, for differentiating MSC in three-dimensional graphene foam
scaffolds into DA neurons collagen coating has been used to enhance the handling strength of
graphene foam for cell culture convenience. Cell adhesion, proliferation and maintenance was
examined by fluorescence microscopy, flow cytometry and electrical stimulation. Material
characterization of the commercially available graphene foam and collagen coated graphene foam
was compared by SEM, Raman spectrometry and electrical conductivity test. These studies will
help develop neural tissue engineered therapies to improve clinical treatments for
neurodegenerative diseases like Parkinson’ disease. As mentioned earlier that DA neurons are
degenerated and lost in case of PD, so cell replacement therapy is an ideal therapeutic approach
for this. Stem cells can be transplanted in the central nervous system and it depends on the cell
type and cell delivery method. Some researchers used poly(N-isopropylacrylamide) (pNIPAM)
hydrogel to facilitate manipulation of neurons which increased the number of viable transplanted
cells in rat hippocampus [206]. In some studies, fibrin gel has been used as an excellent
biocompatible and injectable scaffold and cell carrier promoting cell viability and tissue
regeneration [207].
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The transition from traditional 2D cell culture platforms toward 3D systems seeks to
overcome the limitations of 2D cellular models and mimic the native cellular microenvironment.
Such 3D tissue culture platforms provide the opportunity for further understanding of
structure−function relationships and tissue pathophysiology; as well as facilitate the development
of novel regenerative medical treatments to help restore and strengthen lost functionality [154]. A
critical challenge of this evolution has been the development of biocompatible scaffolding to
simulate the natural extracellular matrix (ECM). Beyond the biological materials such as proteinbased ECMs, novel engineered materials offer improved functionality and customization for
localized chemical delivery and bioactivity monitoring. Among these materials, graphene has
become an excellent alternative because of physical, electrical, and mechanical properties.
In biomedical applications, 3D macroscopic structure is needed as 2D graphene often does
not meet the mass and volume requirements. 3D graphene foam has high specific surface area due
to the porous structure, but low mechanical strength [155]. Future studies should emphasize on
chemically immobilizing the growth factors directly in the GF scaffold so that it would avoid
repeated surgery to deliver the healthy neurons in the brain, derived from patient’s own stem cell.
Mesenchymal Stem Cells have the potential to be differentiated into other tissues and also into
neurons. This has generated great interest about the potential use of MSC for the treatment of
degenerative diseases of the nervous system. Surface chemistry plays an important role for the
adhesion of cells. Biocompatibility of graphene and GO is also important with the use of collagen.
In conclusion, engineering substrates to induce desired cell phenotype and genotype is an
important strategy of scaffold design for tissue-engineering applications. Graphene can be used to
enhance cell adhesion and proliferation of MSCs, and it exhibits a neuro-inductive effect via
spontaneous cell polarization. Graphene films are found to be highly supportive of MSCs growth
and have significant effects on cell morphology, cytoskeletal and nuclear elongation of MSCs [86].
Graphene based 3D scaffold may be a viable platform for neural tissue-engineering applications
and can be used for the research of therapeutic approaches for PD and other neurodegenerative
diseases.
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